DiaMedica Therapeutics Inc [DMAC] stock is trading at $7.16, up 16.61%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DMAC shares have gain 25.39% over the last week, with a monthly amount glided 48.55%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
DiaMedica Therapeutics Inc [NASDAQ: DMAC] stock has seen the most recent analyst activity on October 07, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $7. On June 22, 2023, upgrade upgraded it’s rating to Outperform but maintained its price target of $7 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $27 on April 09, 2021. ROTH Capital initiated its recommendation with a Buy and recommended $38 as its price target on February 17, 2021. Guggenheim started tracking with a Buy rating for this stock on October 30, 2020, and assigned it a price target of $16. In a note dated July 08, 2020, Maxim Group initiated an Buy rating and provided a target price of $14 on this stock.
DiaMedica Therapeutics Inc [DMAC] stock has fluctuated between $3.19 and $6.82 over the past year. Currently, Wall Street analysts expect the stock to reach $8.33 within the next 12 months. DiaMedica Therapeutics Inc [NASDAQ: DMAC] shares were valued at $7.16 at the most recent close of the market. An investor can expect a potential return of 16.34% based on the average DMAC price forecast.
Analyzing the DMAC fundamentals
Gross Profit Margin for this corporation currently stands at 0.0% with Operating Profit Margin at -2.28%, Pretax Profit Margin comes in at -2.14%, and Net Profit Margin reading is -2.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.94, Equity is -0.79 and Total Capital is -1.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.66 points at the first support level, and at 6.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.58, and for the 2nd resistance point, it is at 7.99.
Ratios To Look Out For
For context, DiaMedica Therapeutics Inc’s Current Ratio is 7.55. Also, the Quick Ratio is 7.55, while the Cash Ratio stands at 1.0.
Transactions by insiders
Recent insider trading involved STAHLBERG JAN, 10% Owner, that happened on Aug 25 ’25 when 0.34 million shares were purchased. 10% Owner, STAHLBERG JAN completed a deal on Aug 13 ’25 to buy 0.29 million shares. Meanwhile, 10% Owner STAHLBERG JAN bought 70414.0 shares on Aug 14 ’25.
